Par Pharmaceutical Inc, one of the operating companies of Endo International plc (OTC: ENDPQ), announced on Friday that it has started shipping the first generic version of Allergan's Pylera(R) (bismuth subcitrate potassium, metronidazole, tetracycline hydrochloride) 140 mg, 125 mg and 125 mg capsules in the US.
The company has taken this step subsequent to US Food and Drug Administration approval of its Abbreviated New Drug Application.
Bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride capsules, along with omeprazole, are aimed at treating patients with Helicobacter pylori infection and duodenal ulcer disease (active or history of within the past five years) to eradicate H. pylori.
Accord Healthcare launches Lurasidone HCL tablets
US FDA Accepts the ATI-1501 NDA, According to Appili Therapeutics
Sanofi reports Q4 sales of Dupixent up 42%
Upsher-Smith Laboratories launches Fluoxetine Oral Solution, USP, 20mg/5mL
Astellas Pharma enters into Asset Purchase Agreement with Sandoz
ANI Pharmaceuticals Launches Levocarnitine Tablets USP Following US FDA Approval
Hartness Named to Bryn Pharma Board of Directors
Accord Healthcare adds Bendamustine Lyo. Injection to range of chemotherapy drugs
ANI Pharmaceuticals Receives FDA Approval, Launches Fluoxetine Oral Solution USP
ANI Pharmaceuticals receives FDA approval for Fluoxetine Oral Solution USP
Prasco Laboratories introduces Authorised Generic of ZIOPTAN in partnership with Thea Pharma
ANI Pharmaceuticals declares FDA approval and commercialisation of Trimethoprim Tablets USP
McKinley, Boothe Named to Maxwell Biosciences Board of Directors